Cisplatin plus vindesine in advanced breast cancer: A phase II trial of the EORTC breast cancer cooperative group

R. Paridaens, A. Clarysse, M. Rozencweig, N. Rotmensz, J. C. Heuson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This phase II clinical trial was conducted in a series of patients with advanced breast cancer, refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of cisplatin 100 mg/m2, given as a 24-hr infusion on day 1 and vindesine (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in patients with poor bone marrow reserved (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluated patients, there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. Renal function impairment and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated patients warrants further evaluation of this regimen at an earlier stage of the disease.

Original languageEnglish
Pages (from-to)595-599
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume21
Issue number5
DOIs
Publication statusPublished - 1985

Fingerprint

Vindesine
Cisplatin
Breast Neoplasms
Phase II Clinical Trials
Viscera
Neurologic Manifestations
Antineoplastic Agents
Disease Progression
Bone Marrow
Kidney
Bone and Bones
Drug Therapy
Injections

ASJC Scopus subject areas

  • Oncology

Cite this

Cisplatin plus vindesine in advanced breast cancer : A phase II trial of the EORTC breast cancer cooperative group. / Paridaens, R.; Clarysse, A.; Rozencweig, M.; Rotmensz, N.; Heuson, J. C.

In: European Journal of Cancer and Clinical Oncology, Vol. 21, No. 5, 1985, p. 595-599.

Research output: Contribution to journalArticle

@article{ee7b966f28554aec891336b2f8b03f27,
title = "Cisplatin plus vindesine in advanced breast cancer: A phase II trial of the EORTC breast cancer cooperative group",
abstract = "This phase II clinical trial was conducted in a series of patients with advanced breast cancer, refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of cisplatin 100 mg/m2, given as a 24-hr infusion on day 1 and vindesine (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in patients with poor bone marrow reserved (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluated patients, there were two complete and seven partial remissions for an overall response rate of 20{\%}. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38{\%}); bone, 0/6 (0{\%}); viscera, 6/32 (19{\%}). Transient myelosuppression and gastrointestinal intolerance were almost universal. Renal function impairment and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated patients warrants further evaluation of this regimen at an earlier stage of the disease.",
author = "R. Paridaens and A. Clarysse and M. Rozencweig and N. Rotmensz and Heuson, {J. C.}",
year = "1985",
doi = "10.1016/0197-0186(85)90116-0",
language = "English",
volume = "21",
pages = "595--599",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Cisplatin plus vindesine in advanced breast cancer

T2 - A phase II trial of the EORTC breast cancer cooperative group

AU - Paridaens, R.

AU - Clarysse, A.

AU - Rozencweig, M.

AU - Rotmensz, N.

AU - Heuson, J. C.

PY - 1985

Y1 - 1985

N2 - This phase II clinical trial was conducted in a series of patients with advanced breast cancer, refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of cisplatin 100 mg/m2, given as a 24-hr infusion on day 1 and vindesine (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in patients with poor bone marrow reserved (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluated patients, there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. Renal function impairment and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated patients warrants further evaluation of this regimen at an earlier stage of the disease.

AB - This phase II clinical trial was conducted in a series of patients with advanced breast cancer, refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of cisplatin 100 mg/m2, given as a 24-hr infusion on day 1 and vindesine (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in patients with poor bone marrow reserved (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluated patients, there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. Renal function impairment and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated patients warrants further evaluation of this regimen at an earlier stage of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84886639312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886639312&partnerID=8YFLogxK

U2 - 10.1016/0197-0186(85)90116-0

DO - 10.1016/0197-0186(85)90116-0

M3 - Article

C2 - 4040025

AN - SCOPUS:84886639312

VL - 21

SP - 595

EP - 599

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -